Literature DB >> 10605845

Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination.

L Borg1, E Khuri, A Wells, D Melia, N V Bergasa, A Ho, M J Kreek.   

Abstract

AIMS: To study the efficacy of standard hepatitis B (HB) vaccination in methadone-maintained former intravenous drug users.
DESIGN: HB vaccine was administered to subjects at 0, 1 and 6 months.
SETTING: Two university-affiliated methadone maintenance clinics. PARTICIPANTS: Forty-three HB-unexposed former heroin addicts in methadone maintenance treatment for heroin addiction. MEASUREMENTS: HB surface antibody (anti-HBs) response to the vaccine was assessed at 0, 1, 6 and > or = 12 months; anti-HIV-1 status was also assessed.
FINDINGS: Thirty-seven patients (86%) completed the 6-month vaccination series. Of the 30 anti-HIV-1 seronegative patients who then completed the entire 12-month protocol, 21 (70%) seroconverted (anti-HBs ratio > 2.1) and 19 (63%) were protected (anti-HBs ratio > 10). Two other subjects were anti-HIV-1 seropositive: one was HB-protected at 12 months but later lost immunity. Ten anti-hepatitis C antibody-positive patients completed the 12-month study and six were protected; thus, there was no significant relationship between hepatitis C status and HB vaccine response.
CONCLUSIONS: Standard HB vaccination is both feasible and effective.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10605845     DOI: 10.1046/j.1360-0443.1999.9444894.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  12 in total

1.  Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study.

Authors:  Paula J Lum; Kristen C Ochoa; Judith A Hahn; Kimberly Page Shafer; Jennifer L Evans; Andrew R Moss
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

Review 2.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

Review 3.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

4.  Predictors of HAV/HBV vaccination completion among methadone maintenance clients.

Authors:  Adeline Nyamathi; Karabi Sinha; Barbara Greengold; Allan Cohen; Mary Marfisee
Journal:  Res Nurs Health       Date:  2010-04       Impact factor: 2.228

Review 5.  Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.

Authors:  Brian R Edlin; Thomas F Kresina; Daniel B Raymond; Michael R Carden; Marc N Gourevitch; Josiah D Rich; Laura W Cheever; Victoria A Cargill
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

6.  Treating chronic hepatitis C in recovering opiate addicts: yes, we can.

Authors:  M J Kreek; A H Talal; P Piccolo
Journal:  Dig Liver Dis       Date:  2009-02-23       Impact factor: 4.088

7.  Adherence to hepatitis B virus vaccination at syringe exchange sites.

Authors:  Frederick L Altice; Robert D Bruce; Mary R Walton; Marta I Buitrago
Journal:  J Urban Health       Date:  2005-03-03       Impact factor: 3.671

8.  The effect of vaccinated children on increased hepatitis B immunization among high-risk adults.

Authors:  Deepika L Koya; Elizabeth G Hill; Paul M Darden
Journal:  Am J Public Health       Date:  2008-04-01       Impact factor: 9.308

9.  Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B.

Authors:  Gavin Bart; Paola Piccolo; Linqi Zhang; Ira Jacobson; Robert A Schaefer; Mary Jeanne Kreek
Journal:  Addiction       Date:  2008-04       Impact factor: 6.526

10.  Prevalence and correlates of previous hepatitis B vaccination and infection among young drug-users in New York City.

Authors:  S Amesty; D C Ompad; S Galea; C M Fuller; Y Wu; B Koblin; D Vlahov
Journal:  J Community Health       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.